{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:49:05Z","timestamp":1792054145209,"version":"4.4.0"},"reference-count":104,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"DOI":"10.1080\/13543776.2026.2748593","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T09:55:01Z","timestamp":1791798901000},"page":"1-24","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A patenting perspective of IKZF2 molecular glue degraders (2020-present)"],"prefix":"10.1080","author":[{"given":"Xuqing","family":"Zhang","sequence":"first","affiliation":[{"name":"SK Life Sciences Labs","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05731"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711413165"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.6.782"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0616"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0572"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2010.02.001"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604765113"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25429"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900422"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116680"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkag141.1014"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13866"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.212.supp.1193.4421"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe3981"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe3454"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202317"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01928"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0362-y"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2023.02.005"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.1332"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58431-z"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-021-00802-w"},{"key":"e_1_3_4_31_1","unstructured":"Novartis Pharmaceuticals. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors. ClinicalTrials.gov Identifier: NCT03891953. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03891953"},{"key":"e_1_3_4_32_1","unstructured":"Bristol-Myers Squibb. A study of BMS-986449 with and without nivolumab in participants with advanced solid tumors. ClinicalTrials.gov Identifier: NCT05888831. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05888831"},{"key":"e_1_3_4_33_1","unstructured":"Plexium Australia Pty Ltd. A study to evaluate the safety pharmacokinetics and pharmacodynamics of PLX-4545 in healthy volunteers. Australian New Zealand Clinical Trials Registry Identifier: ACTRN12623001265662. Available from: https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=386484"},{"key":"e_1_3_4_34_1","unstructured":"Novartis Pharmaceuticals. A study of safety and efficacy of KFA115 alone and in combo with pembrolizumab in patients with select advanced cancers. ClinicalTrials.gov Identifier: NCT05544929. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05544929"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00052-4"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400365"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-023-00036-6"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12936"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-852798"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1814446115"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7011"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7269"},{"key":"e_1_3_4_43_1","unstructured":"D\u2019hennezel EMG Gu Y Kattenhorn LM et al.; Novartis AG Switzerland. Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives. WO2021260528A1. 2021."},{"key":"e_1_3_4_44_1","unstructured":"Bonazzi S Crystal A Cameron JS et al.; Novartis AG Switzerland. Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives. WO2020128972A1. 2020."},{"key":"e_1_3_4_45_1","unstructured":"Beckwith REJ Bonazzi S Cernijenko A et al.; Novartis AG Switzerland. 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2 6-dione misc derivatives and uses thereof. WO2020165833A1. 2020."},{"key":"e_1_3_4_46_1","unstructured":"Beckwith REJ Bonazzi S Cernijenko A et al.; Novartis AG Switzerland. Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives and uses thereof. WO2020165834A1. 2020."},{"key":"e_1_3_4_47_1","unstructured":"Beckwith REJ Bonazzi S Cernijenko A et al.; Novartis AG Switzerland. Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives and uses thereof. WO2022029573A1. 2022."},{"key":"e_1_3_4_48_1","unstructured":"Beckwith REJ Bonazzi S Cernijenko A et al.; Novartis AG Switzerland. 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives and their use in the treatment of Ikaros family zinc finger 2 (IKZF2)-dependent diseases. WO2020012337A1. 2020."},{"key":"e_1_3_4_49_1","unstructured":"Adcock C Bonazzi S Cernijenko A et al.; Novartis AG Switzerland. 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2 6-dione derivatives and their use in the treatment of Ikaros family zinc finger 2 (IKZF2)-dependent diseases. WO2020012334A1. 2020."},{"key":"e_1_3_4_50_1","volume-title":"Presented at the ACS Fall 2026 national meeting","author":"Bonazzi S","year":"2026","unstructured":"Bonazzi S. KFA115: a first-in-class selective IKZF2 (Helios) and IKZF4 (Eos) molecular glue degrader for immuno-oncology. In: Presented at the ACS Fall 2026 national meeting. Chicago IL: MEDI First Time Disclosures Session; 2026 Aug 26."},{"key":"e_1_3_4_51_1","unstructured":"Degnan AP Kumi GK Tebben AJ et al.; Bristol-Myers Squibb Company USA. Substituted oxoisoindoline compounds for the treatment of cancer. WO2021194914A1. 2021."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6c01271"},{"key":"e_1_3_4_53_1","unstructured":"Chen Y Kumi GK Huang A et al.; Bristol Myers Squibb Co. USA. Pyridinyl substituted oxoisoindoline compounds. WO2022216644A1. 2022."},{"key":"e_1_3_4_54_1","unstructured":"Cherney EC Purandare AV Kumi GK et al.; Bristol Myers Squibb Co. USA. Spirocyclic substituted oxoisoindolinyl piperidine-2 6-dione compound. WO2024254227A1. 2024."},{"key":"e_1_3_4_55_1","unstructured":"Kumi GK Purandare AV Cherney EC et al.; Bristol Myers Squibb Co. USA. Substituted oxoisoindolinyl piperidine-2 6-dione compound as anticancer agent. WO2024263853A1. 2024."},{"key":"e_1_3_4_56_1","unstructured":"Shirude PS Shimpukade BD Penmetsa SBVK et al.; Bristol Myers Squibb Co. USA. Substituted azetidinyl oxoisoindolinyl piperidine-2 6-dione compounds. WO2025064197A1. 2025."},{"key":"e_1_3_4_57_1","unstructured":"Shirude PS Shimpukade BD Penmetsa SBVK et al.; Bristol Myers Squibb Co. USA. Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2 6-dione compounds for use in the treatment of cancer. WO2025226767A1. 2025."},{"key":"e_1_3_4_58_1","unstructured":"Degnan AP Kumi GK Huang A et al.; Bristol Myers Squibb Co. USA. Compounds useful as inhibitors of Helios protein. US20210147383A1. 2021."},{"key":"e_1_3_4_59_1","unstructured":"Kumi GK Purandare AV Li G et al.; Bristol Myers Squibb Co. USA. Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer. WO2022216573A1. 2022."},{"key":"e_1_3_4_60_1","unstructured":"D\u2019agostino LA Kumi GK Liu H et al.; Celgene Corp.; Bristol Myers Squibb Co. USA. Compounds and compositions for selective degradation of engineered proteins. WO2024167999A1. 2024."},{"key":"e_1_3_4_61_1","unstructured":"Qin LY Ruan Z Purandare AV et al.; Bristol Myers Squibb Co. USA. Substituted phenyl oxazolone compounds. WO2024233514A1. 2024."},{"key":"e_1_3_4_62_1","unstructured":"Penmetsa SBVK Nair SK Shimpukade BD et al.; Bristol Myers Squibb Co. USA. Substituted oxazolone compound for decreasing levels of IKZF1-4 proteins. WO2024249540A1. 2024."},{"key":"e_1_3_4_63_1","unstructured":"Shirude PS Penmetsa SBVK Shimpukade BD et al.; Bristol Myers Squibb Co. USA. Substituted phenyl oxooxazolyl piperidine dione compounds. WO2025049840A1. 2025."},{"key":"e_1_3_4_64_1","unstructured":"Qin LY Ruan Z Cherney EC et al.; Bristol Myers Squibb Co. USA. Chemical compounds useful for degrading proteins. WO2026080794A1. 2026."},{"key":"e_1_3_4_65_1","unstructured":"Bristol-Myers Squibb. A study of BMS-986482 alone or as combination therapy in participants with advanced solid tumors. ClinicalTrials.gov identifier: NCT06697197. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06697197"},{"key":"e_1_3_4_66_1","unstructured":"Yang P Bailey S; Plexium Inc. USA. Aryl compounds and pharmaceutical compositions that modulate IKZF2. WO2023283425A1. 2023."},{"key":"e_1_3_4_67_1","unstructured":"Yang P Bailey S; Plexium Inc. USA. Salts and solid forms of compounds that modulate IKZF2. WO2025024823A1. 2025."},{"key":"e_1_3_4_68_1","unstructured":"Yang P Bailey S; Plexium Inc. USA. Cycloalkyl compounds and pharmaceutical compositions that modulate IKZF2. WO2023283430A1. 2023."},{"key":"e_1_3_4_69_1","unstructured":"Yang P Bailey S; Plexium Inc. USA. Heterocycloalkyl and heteroaryl compounds and pharmaceutical compositions that modulate IKZF2. WO2023283428A1. 2023."},{"key":"e_1_3_4_70_1","unstructured":"Yang P Bailey S; Plexium Inc. USA. Spirocycloalkyl compounds and pharmaceutical compositions that modulate IKZF2. WO2024148088A1. 2024."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.1393"},{"key":"e_1_3_4_72_1","unstructured":"Huang Y Thompson P; Plexium Inc. USA. Combination therapies comprising IKZF2 degrader compounds for treating disease involving IKZF2. WO2026102277A1. 2026."},{"key":"e_1_3_4_73_1","unstructured":"Chen Z Rohan REJ Zhang X et al.; Oncopia Therapeutics Inc. d\/b\/a Proteovant Therapeutics Inc.; The Regents of the University of Michigan USA. IKZF2 degraders and uses thereof. WO2023183540A1. 2023."},{"key":"e_1_3_4_74_1","unstructured":"Zhang X Wang S Kirchhoff P et al.; Oncopia Therapeutics Inc. d\/b\/a Proteovant Therapeutics Inc.; The Regents of the University of Michigan USA. IKZF2 degraders and uses thereof. WO2023201012A1. 2023."},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2024.100797"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature18611"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38430"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0129-x"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-018-0055-y"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2025.08.019"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14610"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16979"},{"key":"e_1_3_4_84_1","unstructured":"Deng Q Zhang X; Oncopia Therapeutics Inc. d\/b\/a Proteovant Therapeutics Inc. USA. Bicyclic heteroaryl-containing compounds as IKZF2 degraders. WO2023183919A1. 2023."},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00668"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2025.130263"},{"key":"e_1_3_4_87_1","unstructured":"Verano A Wang E Nowak R et al.; Dana-Farber Cancer Institute Inc. USA. Small molecule degraders of Helios and methods of use. WO2020117759A1. 2020."},{"key":"e_1_3_4_88_1","unstructured":"Verano A Wang E Nowak R et al.; Dana-Farber Cancer Institute Inc. USA. Small molecule degraders of Helios and methods of use. US20220177443A1. 2022."},{"key":"e_1_3_4_89_1","unstructured":"Gray NS Liu H Zhang T et al.; Dana-Farber Cancer Institute Inc. USA. Small molecule degraders of Helios and methods of use. WO2021087093A1. 2021."},{"key":"e_1_3_4_90_1","unstructured":"Bear B Petrilli W Liu H et al.; Neomorph Inc.; Dana-Farber Cancer Institute Inc. USA. Piperidinyl small molecule degraders of Helios and methods of use. WO2022081976A1. 2022."},{"key":"e_1_3_4_91_1","unstructured":"Petrilli WL Jones LH Liu H et al.; Neomorph Inc.; Dana-Farber Cancer Institute Inc. USA. Substituted 2-(2 6-dioxopiperidin-3-yl)-5-(1-piperidin-4-yl)isoindoline-1 3-dione derivatives and uses thereof. WO2022232536A1. 2022."},{"key":"e_1_3_4_92_1","unstructured":"Zhang T Jones LH Liu H et al.; Dana-Farber Cancer Institute Inc. USA. Phthalimido cereblon complex binders and transcription factor degraders and methods of use. WO2022232391A1. 2022."},{"key":"e_1_3_4_93_1","unstructured":"Woo CM Miyamoto DK Kharas M et al.; Memorial Sloan Kettering Cancer Center; Harvard University USA. 5-amino-2-piperidinon-3-yl-1-oxoisoindoline derivatives for degradation of IKZF2 degraders. WO2021222542A1. 2021."},{"key":"e_1_3_4_94_1","unstructured":"Woo CM Miyamoto DK Curnutt NM et al.; Memorial Sloan Kettering Cancer Center; Harvard University USA. IKZF2 and CK1-alpha degrading compounds and uses thereof. WO2024059107A1. 2024."},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.010"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01736"},{"key":"e_1_3_4_97_1","unstructured":"C4 Therapeutics Inc. Study to assess the safety and tolerability of CFT7455 in relapsed\/refractory non-Hodgkin\u2019s lymphoma or multiple myeloma. ClinicalTrials.gov identifier: NCT04756726. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04756726"},{"key":"e_1_3_4_98_1","unstructured":"Nasveschuk CG Henderson JA Moustakim M et al.; C4 Therapeutics Inc. USA. Tricyclic ligands for degradation of IKZF2 or IKZF4. WO2022081925A1. 2022."},{"key":"e_1_3_4_99_1","unstructured":"Blomgren PA Du Z Kim M et al.; Gilead Sciences Inc. USA. Ikaros zinc finger family degraders and uses thereof. WO2023122615A1. 2023."},{"key":"e_1_3_4_100_1","unstructured":"Xiang JS Wu L Liu Y et al.; Hangzhou Polymed Biopharmaceuticals Inc. P.R. China. Heterocyclic compound and composition and use thereof. WO2025067466A1. 2025."},{"key":"e_1_3_4_101_1","unstructured":"Mei D Wu X Lv S et al.; Suzhou Guokuang Pharmtech Co Ltd. P. R. China. IKZF2 degradation agent pharmaceutical composition comprising same and use thereof. WO2023155710A1. 2023."},{"key":"e_1_3_4_102_1","unstructured":"Hu W Wang L Cai X et al.; Chengdu Fendi Pharmaceutical Co Ltd. P. R. China. Halogen-substituted isoindoline compound and use thereof. WO2023207241A1. 2023."},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01086"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6c00500"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2026-CT006"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT150"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2748593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2748593","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2748593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:25:29Z","timestamp":1792052729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2748593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":104,"alternative-id":["10.1080\/13543776.2026.2748593"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2748593","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}